Related Experiment Video

Updated: Apr 20, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Anti-HER2 therapy in elderly breast cancer patients

Masataka Sawaki1

  • 11-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. m-sawaki@aichi-cc.jp.

Reviews on Recent Clinical Trials
|December 3, 2014
PubMed

Insights

Anti-HER2 therapies like trastuzumab are standard for HER2-overexpressing breast cancer. This review examines anti-HER2 therapy effectiveness and approaches in elderly patients, who are often underrepresented in clinical trials.

Area of Science:

  • Oncology
  • Clinical Pharmacology

Background:

  • Anti-HER2 therapies (trastuzumab, lapatinib, T-DM1, pertuzumab) are standard for HER2-overexpressing breast cancer.
  • Elderly patients are underrepresented in clinical trials, limiting data on anti-HER2 therapy efficacy in this demographic.

Purpose of the Study:

  • To review the current data on anti-HER2 therapy in elderly patients with HER2-overexpressing breast cancer.
  • To explore strategies for optimizing anti-HER2 treatment effectiveness in this population.

Main Methods:

  • Literature review of studies focusing on anti-HER2 therapy in elderly breast cancer patients.
  • Analysis of treatment outcomes and adverse events in older adults.

Main Results:

  • Limited data exists on anti-HER2 therapy outcomes in elderly populations.
  • Further research is needed to establish optimal dosing and management strategies for elderly patients.

Conclusions:

  • Anti-HER2 therapy can be effective in elderly patients, but requires careful consideration of individual factors.
  • Tailored treatment approaches are necessary to maximize efficacy and minimize toxicity in older adults receiving anti-HER2 therapy.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.3K

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
376
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
349
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
830